The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.125
Bid: 3.00
Ask: 3.25
Change: -0.175 (-5.30%)
Spread: 0.25 (8.333%)
Open: 3.075
High: 3.38
Low: 3.10
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

25 Oct 2023 09:48

RNS Number : 2658R
Cavendish Securities PLC
25 October 2023

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

24/10/23

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

ORD 0.1p

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

279288

0.01

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

279288

0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 0.1p

Sales

4000

1.57

1.57

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

25/10/23

Contact name:

Angela Teodorescu

Telephone number:

02037724641

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FEOUVSWROBURURA
Date   Source Headline
21st Jun 20239:38 amRNSForm 8.5 (EPT/RI)
20th Jun 202312:49 pmRNSForm 8.5 - Allergy Therapeutics plc
20th Jun 20239:57 amBUSForm 8.3 - The Allergy Therapeutics Plc
20th Jun 20239:05 amRNSForm 8.5 (EPT/RI)
19th Jun 20237:30 amRNSRestoration - Allergy Therapeutics PLC
19th Jun 20237:01 amRNSInterim Results and Lifting Suspension in Trading
19th Jun 20237:00 amRNSPublication of Annual Report and Accounts 2022
9th Jun 20237:00 amRNSAllergy Therapeutics shares key findings at EAACI
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
27th Apr 20232:15 pmRNSResult of General Meeting
24th Apr 20237:00 amRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
21st Apr 20237:00 amRNSFORM 8 (OPD) – Allergy Therapeutics plc
20th Apr 20235:29 pmRNSProject Zebra Rule 2.9 Announcement
19th Apr 20237:00 amRNSSkin-prick testing completes in PROTECT Trial
17th Apr 20232:30 pmRNSForm 8 OPD SkyGem Acquisition Limited Replacement
17th Apr 202310:30 amRNSForm 8 (OPD) SkyGem Acquisition Limited
11th Apr 202310:10 amBUSForm 8.3 - The Allergy Therapeutics Plc
6th Apr 20232:01 pmRNS£40.75 million Facility with Equity Financing
6th Apr 20232:01 pmRNSStatement Regarding Possible Mandatory Cash Offer
6th Apr 20232:00 pmRNSTrading and Business Update
29th Mar 20237:00 amRNSPublication of Interim Results Delayed
27th Mar 20237:00 amRNSPatients dosed in VLP Peanut PROTECT trial
8th Mar 20235:28 pmRNSBlock Listing Interim Review
3rd Mar 20237:00 amRNSPDMR Dealing
7th Feb 20236:29 pmRNSResult of AGM
20th Jan 20237:00 amRNSHalf-Year Trading Update 2023
13th Jan 20235:27 pmRNSNOTICE OF 2022 ANNUAL GENERAL MEETING
3rd Jan 20237:30 amRNSSuspension - Allergy Therapeutics plc
29th Dec 202211:05 amRNSSecond Price Monitoring Extn
29th Dec 202211:00 amRNSPrice Monitoring Extension
29th Dec 20229:05 amRNSSecond Price Monitoring Extn
29th Dec 20229:00 amRNSPrice Monitoring Extension
29th Dec 20227:00 amRNSAnnual Report and Accounts Delayed
28th Dec 20227:00 amRNSDirector Resignation
8th Dec 20227:00 amRNSKey updates on Grass MATA MPL and VLP Peanut
6th Dec 20227:00 amRNSAppointment of Non-Executive Directors
21st Nov 20227:00 amRNSAppointment of Interim CFO
28th Oct 20227:00 amRNSAllergy to resume UK manufacturing production
19th Oct 20223:39 pmRNSHolding(s) in Company
17th Oct 20221:27 pmRNSAllergy Therapeutics – Result of GM
4th Oct 20227:00 amRNSUK manufacturing update
29th Sep 202212:00 pmRNSAllergy Therapeutics at Investor Meet Company
29th Sep 20227:00 amRNSSubscription and Debt Financing
29th Sep 20227:00 amRNSUnaudited Preliminary Results 2022
5th Sep 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
2nd Sep 20224:50 pmRNSTotal Voting Rights
2nd Aug 202212:58 pmRNSBlock Listing Interim Review
15th Jul 20227:00 amRNSTrading Update and Notice of Results
1st Jul 20227:00 amRNSAllergy Therapeutics at EAACI Congress 2022
26th May 20227:00 amRNSNick Wykeman to step down as CFO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.